Showing results (1391-1400 of 1,523) with videos related to
Sort By:
Pageof 153
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2021
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLCYi-Long Wu, Thomas John, Christian Grohe, et al.Ebiomedicine|April 28, 2019
Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trialYi-Chen Zhang, Zhi-Hong Chen, Xu-Chao Zhang, et al.Cancer Cell|August 13, 2021
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 studyQing Zhou, Chong-Rui Xu, Ying Cheng, et al.Thoracic Cancer|April 8, 2022
Intratumoral genetic and immune microenvironmental heterogeneity in T4N0M0 (diameter ≥ 7 cm) non-small cell lung cancersJia Tao Zhang, Song Dong, Li Yan Ji, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 21, 2022
Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People's Republic of ChinaShun Lu, Qing Zhou, Xiaoqing Liu, et al.Lung Cancer (Amsterdam, Netherlands)|December 15, 2020
Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)Shun Lu, Jie Wang, Ying Cheng, et al.European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|November 17, 2023
Lack of incremental value of three-dimensional measurement in assessing invasiveness for lung cancerMeng-Min Wang, Jia-Qi Li, Shi-Hua Dou, et al.Annals of Nuclear Medicine|December 25, 2023
Impact of preoperative [18F]FDG PET/CT vs. contrast-enhanced CT in the staging and survival of patients with clinical stage I and II non-small cell lung cancer: a 10-year follow-up studyJun-Tao Lin, Xiang-Meng Li, Wen-Zhao Zhong, et al.JAMA Oncology|June 4, 2023
Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical TrialJulien Mazieres, Paul K Paik, Marina C Garassino, et al.The New England Journal of Medicine|April 10, 2024
Alectinib in Resected ALK-Positive Non-Small-Cell Lung CancerYi-Long Wu, Rafal Dziadziuszko, Jin Seok Ahn, et al.Pageof 153